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Regulatory T cells (Treg) constitute a small subset of immunosuppressive CD4+ T cells. Studies have shown 
that imbalanced or aberrant Treg function can result in autoimmune disorders. The importance of Tregs in 
dampening immune responses has been described in multiple studies and Treg immunotherapies are being 
explored to develop personalized therapies for various autoimmune diseases. Scalable commercial 
development of Treg therapies suffers similar challenges as other T cell immunotherapies: biosafety and supply 
chain concerns of human serum and limitations regarding bioprocess development due to serum variability. 
Additionally, there a challenges regarding Treg isolation for both magnetically isolated (blockade of CD25+ 
epitope may affect function and low purity) and flow cytometry sorted Tregs (low numbers and viability). In 
addition, the starting population and purity (measured by FOXP3 expression) can be low, resulting in small cell 
numbers post expansion which can impact dose escalation studies. To address these challenges, we are 
developing a serum-free, animal origin component – free, defined medium and Treg optimized Dynabeads™. 
Our strategy was to exploit metabolic differences between Tregs and conventional Tcells as well as optimizing 
the level of activation ligands to develop a defined Treg manufacturing system. Using design of experiment 
(DOE) approaches we explored factors described in the literature to be associated with Treg development. DOE 
studies were followed by testing in combination with Treg Dynabeads™ in development. Feasibility was 
evaluated with positively selected Tregs (CD4+CD25+CD127lo, n=5). Tregs cultured in our system achieve 
higher FOXP3+ frequencies (>60% FOXP3+) outperforming control containing 10% human serum (~30% 
FOXP3+). In summary, our results suggest that serum can be eliminated from Treg workflows to generate highly 
suppressive enriched FOXP3+ Treg immunotherapy product. We believe that our defined serum-free medium 
and Dynabeads™ Treg system will enable the development of better immunotherapies for autoimmunity. 
 
